Commodore Capital LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Commodore Capital LP reported 39 stock positions worth $1.5 billion. Its top holding was Merus (MRUS) at 13.1% of the portfolio, followed by Vera Therapeutics (VERA, 9.1%) and Nuvalent Class A (NUVL, 7.5%). Compared with Q4 2023, it opened 12 new positions, sold out of 5, added to 11 and reduced 11. The biggest buy was a new position in Mind Medicine Mindmed and the biggest sale Rhythm Pharmaceuticals (RYTM, shares −32%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001831942
- Portfolio Value
- $1.5B (Q1 2024)
- SEC Filing
- 0001831942-24-000006 ↗ filed May 15, 2024
Holdings Value
Holdings 39 stocks · $1.5B
| MRUS Merus NV | 13.13% | 4,360,000 | $196.3M | Reduce -8.2% |
| VERA Vera Therapeutics Inc. | 9.13% | 3,165,000 | $136.5M | Reduce -41.9% |
| NUVL Nuvalent Inc. Class A | 7.47% | 1,487,756 | $111.7M | Add +11.8% |
| XENE Xenon Pharmaceuticals Inc. | 6.24% | 2,167,793 | $93.3M | No change |
| SYRE Spyre Therapeutics Inc. | 4.78% | 1,884,084 | $71.5M | No change |
| ELVN Enliven Therapeutics Inc. | 4.67% | 3,973,245 | $69.9M | Add +36.9% |
| PCVX Vaxcyte Inc. | 3.93% | 860,000 | $58.7M | Reduce -21.8% |
| MIND MEDICINE MINDMED INC | 3.67% | 5,833,333 | $54.8M | New |
| ALPN Alpine Immune Sciences Inc. | 3.64% | 1,375,000 | $54.5M | Reduce -14.6% |
| ARVN Arvinas Inc. | 3.52% | 1,275,000 | $52.6M | Add +27.5% |
| RYTM Rhythm Pharmaceuticals Inc. | 3.04% | 1,050,000 | $45.5M | Reduce -32.3% |
| COGT Cogent Biosciences Inc. | 2.89% | 6,425,000 | $43.2M | Add +15.4% |
| PHVS Pharvaris NV | 2.67% | 1,725,000 | $39.9M | Add +115.6% |
| CLDX Celldex Therapeutics Inc. | 2.43% | 866,468 | $36.4M | Add +23.4% |
| NKTX Nkarta Inc. | 2.29% | 3,165,000 | $34.2M | Add +15.9% |
| VRDN Viridian Therapeutics Inc. | 2.27% | 1,934,653 | $33.9M | Add +0.6% |
| CELC Celcuity Inc. | 2.25% | 1,555,954 | $33.6M | Reduce -11.3% |
| KURA Kura Oncology Inc. | 2.18% | 1,525,000 | $32.5M | Add +22.2% |
| CCCC C4 Therapeutics Inc. | 1.86% | 3,410,384 | $27.9M | Reduce -10.3% |
| ORIC Oric Pharmaceuticals Inc. | 1.84% | 2,000,000 | $27.5M | New |
| ABVX Abivax SA-ADR | 1.81% | 1,895,003 | $27.1M | No change |
| CATX Perspective Therapeutics Inc. | 1.68% | 21,052,631 | $25.1M | New |
| IMVT Immunovant Inc. | 1.62% | 750,990 | $24.3M | Reduce -24.9% |
| KYTX Kyverna Therapeutics Inc. | 1.52% | 912,189 | $22.7M | New |
| ENGN Engene Holdings Inc. | 1.42% | 1,250,000 | $21.2M | New |
| APGE Apogee Therapeutics Inc. | 1.29% | 290,000 | $19.3M | Add +16.0% |
| CABA Cabaletta Bio Inc. | 1.25% | 1,100,000 | $18.8M | Reduce -42.1% |
| AUTL Autolus Therapeutics PLC | 0.98% | 2,300,000 | $14.7M | New |
| THRD Third Harmonic Bio Inc. | 0.79% | 1,250,000 | $11.8M | Add +76.9% |
| NGNE Neurogene Inc. | 0.68% | 200,000 | $10.2M | New |
| ADVM Adverum Biotechnologies Inc. | 0.62% | 657,333 | $9.3M | New |
| VTGN Vistagen Therapeutics Inc. | 0.56% | 1,575,000 | $8.3M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 0.51% | 318,851 | $7.6M | New |
| SLNO Soleno Therapeutics Inc. | 0.49% | 169,533 | $7.3M | Reduce -75.8% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.35% | 500,000 | $5.2M | New |
| MGNX Macrogenics Inc. | 0.29% | 295,020 | $4.3M | New |
| ACET Adicet Bio Inc. | 0.22% | 1,374,320 | $3.2M | New |
| SABS Sab Biotherapeutics Inc. | 0.06% | 183,174 | $832K | Reduce -90.0% |
| DBV TECHNOLOGIES S A | 0.00% | 92,687 | $69K | No change |
Portfolio Sells Q4 2023 → Q1 2024
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -32.3% | 3.04% | −3.18 |
| CABA Cabaletta Bio Inc. | Reduce -42.1% | 1.25% | −2.51 |
| PCVX Vaxcyte Inc. | Reduce -21.8% | 3.93% | −2.11 |
| RYZB Rayzebio Inc. | Sold out | 0.00% | −2.08 |
| IMVT Immunovant Inc. | Reduce -24.9% | 1.62% | −2.06 |
| SLNO Soleno Therapeutics Inc. | Reduce -75.8% | 0.49% | −1.98 |
| HARP Harpoon Therapeutics Inc. | Sold out | 0.00% | −1.49 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −1.15 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −1.05 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −0.66 |
| SABS Sab Biotherapeutics Inc. | Reduce -90.0% | 0.06% | −0.05 |
| CCCC C4 Therapeutics Inc. | Reduce -10.3% | 1.86% | −0.01 |
| CELC Celcuity Inc. | Reduce -11.3% | 2.25% | +0.01 |
| ALPN Alpine Immune Sciences Inc. | Reduce -14.6% | 3.64% | +0.96 |
| MRUS Merus NV | Reduce -8.2% | 13.13% | +1.72 |
| VERA Vera Therapeutics Inc. | Reduce -41.9% | 9.13% | +1.80 |
Portfolio Buys Q4 2023 → Q1 2024
| MIND MEDICINE MINDMED INC | New | 3.67% | +3.67 |
| ORIC Oric Pharmaceuticals Inc. | New | 1.84% | +1.84 |
| CATX Perspective Therapeutics Inc. | New | 1.68% | +1.68 |
| KYTX Kyverna Therapeutics Inc. | New | 1.52% | +1.52 |
| ENGN Engene Holdings Inc. | New | 1.42% | +1.42 |
| ELVN Enliven Therapeutics Inc. | Add +36.9% | 4.67% | +1.16 |
| AUTL Autolus Therapeutics PLC | New | 0.98% | +0.98 |
| NKTX Nkarta Inc. | Add +15.9% | 2.29% | +0.71 |
| PHVS Pharvaris NV | Add +115.6% | 2.67% | +0.70 |
| NGNE Neurogene Inc. | New | 0.68% | +0.68 |
| APGE Apogee Therapeutics Inc. | Add +16.0% | 1.29% | +0.68 |
| ADVM Adverum Biotechnologies Inc. | New | 0.62% | +0.62 |
| KURA Kura Oncology Inc. | Add +22.2% | 2.18% | +0.61 |
| SNDX Syndax Pharmaceuticals Inc. | New | 0.51% | +0.51 |
| BBOT Bridgebio Oncology Therapeut | New | 0.35% | +0.35 |
| MGNX Macrogenics Inc. | New | 0.29% | +0.29 |
| ACET Adicet Bio Inc. | New | 0.22% | +0.22 |
| THRD Third Harmonic Bio Inc. | Add +76.9% | 0.79% | +0.11 |
| COGT Cogent Biosciences Inc. | Add +15.4% | 2.89% | +0.03 |
| CLDX Celldex Therapeutics Inc. | Add +23.4% | 2.43% | −0.00 |
| ARVN Arvinas Inc. | Add +27.5% | 3.52% | −0.08 |
| NUVL Nuvalent Inc. Class A | Add +11.8% | 7.47% | −1.09 |
| VRDN Viridian Therapeutics Inc. | Add +0.6% | 2.27% | −1.40 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $1.7B | RLAY, ELVN, ALKS, COGT, AMLX |
| Q1 2026 | 36 | $1.7B | RLAY, ALKS, ELVN, COGT, SYRE |
| Q4 2025 | 33 | $1.5B | RLAY, ALKS, TYRA, XENE, SYRE |
| Q3 2025 | 37 | $2.0B | MRUS, NUVL, XENE, COGT, ELVN |
| Q2 2025 | 33 | $1.4B | MRUS, NUVL, XENE, ELVN, AGIO |
| Q1 2025 | 31 | $1.4B | MRUS, NUVL, ELVN, SLNO, XENE |
| Q4 2024 | 31 | $1.4B | MRUS, PCVX, NUVL, XENE, ELVN |
| Q3 2024 | 36 | $1.6B | MRUS, VERA, XENE, PCVX, ELVN |
| Q2 2024 | 35 | $1.5B | MRUS, NUVL, XENE, PCVX, ELVN |
| Q1 2024 | 39 | $1.5B | MRUS, VERA, NUVL, XENE, SYRE |